NEW YORK, January 27, 2017 /PRNewswire/ --
Stock-Callers.com focuses its attention to four equities in the MedicalAppliances and Equipment space today: Sunshine Heart Inc. (NASDAQ: SSH), Globus Medical Inc. (NYSE: GMED), Align Technology Inc. (NASDAQ: ALGN), and ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ). These companies are part of the Healthcare sector which extended
Eden Prairie, Minnesota headquartered Sunshine Heart Inc.'s stock finished Thursday's session 14.66% higher at $6.65 with a total trading volume of 873,096 shares. The Company's shares have advanced 1,446.51% in the past month, 2,038.26% over the previous three months, and 1,800.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 407.45% and 716.42%, respectively. Furthermore, shares of Sunshine Heart, which develops technologies for cardiac and coronary diseases, have a Relative Strength Index (RSI) of 71.48.
On January 12th, 2017, Sunshine announced a 1-for-30 reverse split of its common stock, effective at 5:00 pm ET the same day. At Sunshine's special meeting of stockholders on January 09th, 2017, the Company's stockholders authorized the Board of Directors to amend the Fourth Amended and Restated Certificate of Incorporation, as amended, of the Company to effect a reverse stock split at a ratio in the range of 1-for-20 to 1-for-60, as per the discretion of its board. See our free and comprehensive research report on SSH at:
Shares in Audubon, Pennsylvania headquartered Globus Medical Inc. ended at $25.97, down 0.65% from the last trading session. The stock recorded a trading volume of 453,111 shares. The Company's shares have gained 5.78% in the last one month, 14.51% over the previous three months, and 4.68% since the start of this year. The stock is trading 8.74% above its 50-day moving average and 10.05% above its 200-day moving average. Moreover, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 60.79.
On January 10th, 2017, Globus Medical for its preliminary unaudited sales results announced that it anticipates Q4 2016 sales of approximately $151.6 million, an increase of 6.3% as reported, or 6.6% in constant currency, over Q4 2015. The Company's Full year 2016 estimated sales are expected to be approximately $564.0 million, an increase of 3.5% as reported, or 3.8% in constant currency, over the prior year. GMED free research report PDF is just a click away at:
San Jose, California headquartered Align Technology Inc.'s stock ended yesterday's session 1.26% lower at $92.23 with a total trading volume of 594,581 shares. The Company's shares have advanced 5.41% in the previous three months. The stock is trading 5.21% above its 200-day moving average. Additionally, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services for use in dentistry, orthodontics, and dental records storage in the US and internationally, have an RSI of 40.59.
On January 09th, 2017, Align announced that Lynn Pendergrass will join the Company on February 27th, 2017 in the newly created position of Vice President and Managing Director of the Americas region. Pendergrass brings over 20 years' experience running global organizations across a range of industries including consumer, technology, industrial, and pharmaceutical. Sign up for your complimentary report on ALGN at:
At the close on Thursday, shares in Pleasanton, California headquartered ZELTIQ Aesthetics Inc. recorded a trading volume of 438,075 shares. The stock finished 1.06% lower at $42.86. The Company's shares have gained 16.34% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 0.33% and 20.68%, respectively. Furthermore, shares of ZELTIQ Aesthetics, which engages in developing and commercializing non-invasive products for the selective reduction of fat, have an RSI of 52.89.
On January 04th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $48 a share to $58 a share.
On January 26th, 2017, ZELTIQ announced that CoolSculpting® is FDA-cleared for upper arms, making it the only non-invasive fat removal technology cleared by the FDA to address this body area. The Company announced that it will be launching the CoolAdvantage Petite applicator for the CoolSculpting system in order to optimize the performance of CoolSculpting in the upper arms, with full commercial release targeted for the middle part of the year. Register for free on Stock-Callers.com and download the latest research report on ZLTQ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Adult immunization is needed for adults whose mandatory childhood vaccines were either missed out ...
Snake antivenom is a medicine used for the treatment of patients suffering from snake envenomation.
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast ...View All